172 related articles for article (PubMed ID: 21548194)
1. [Update regarding the role of biomarkers in early diagnosis of non-small cell bronchopulmonary cancer].
Dragomir A; Moldoveanu E; Mihălţan F
Pneumologia; 2011; 60(1):7, 9-13. PubMed ID: 21548194
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
[TBL] [Abstract][Full Text] [Related]
3. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
4. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
5. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
6. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
8. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
Lazarev SM; Massard Zh; Reshetov AV; Nikolaev GV; Volgin GN; Osipov EV; Lomteva EIu; Nokhrin AV; Kakysheva OE
Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
[TBL] [Abstract][Full Text] [Related]
9. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
11. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
12. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
[TBL] [Abstract][Full Text] [Related]
13. [Tumor markers used in diagnosis and monitoring of primary bronchopulmonary carcinoma].
Mahler B
Pneumologia; 2008; 57(3):175-7. PubMed ID: 18998332
[TBL] [Abstract][Full Text] [Related]
14. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
[TBL] [Abstract][Full Text] [Related]
15. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
16. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
17. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer.
Wu GP; Ba J; Zhao YJ; Wang EH
Acta Cytol; 2007; 51(4):679-80. PubMed ID: 17718156
[No Abstract] [Full Text] [Related]
19. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
Schneider J; Velcovsky HG; Morr H; Katz N; Neu K; Eigenbrodt E
Anticancer Res; 2000; 20(6D):5053-8. PubMed ID: 11326667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]